ARHGEF17

Across TCGA pan-cancer cohorts, ARHGEF17 RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of ARHGEF17’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where ARHGEF17 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ARHGEF17 is over-expressed in tumor, although a few such as BLCA and LUAD show the opposite, repressed pattern.

HNSC, KIRC, and BLCA are the cancer types where ARHGEF17 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARHGEF17 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.975	<.001	11	view →
KIRC	Female	All	+0.823	<.001	9	view →
BLCA	Male	IV	−2.140	.001	8	view →
LIHC	Female	II,III,IV	+1.276	<.001	7	view →
LUAD	Female	All	−0.757	<.001	7	view →
LUSC	Female	All	−1.234	<.001	6	view →
KIRP	Male	All	−0.885	<.001	5	view →
UCEC	All	All	−1.077	<.001	4	view →
BRCA	Female	All	−0.399	<.001	4	view →
CHOL	All	All	+2.533	<.001	3	view →
PRAD	All	All	−0.637	<.001	2	view →
READ	Female	All	−1.318	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

ARHGEF17–HNSC

Open the HNSC breakdown →